Challenged now, charged for tomorrow

Soft sales, solid GM and opex

EBITDA NOK 4m, vs us at NOK 7 due to lower sales. Inventories coming down, improving CF

Cinclus: preparations on track to start phase 3 trial

Cinclus Pharma reported its Q3'24 results with a cash position at SEK644.2m and an EBIT at SEK(39.15m). On the operational side, i) all is on track to recruit the first patient for its phase 3 trial in 2025, with topline data on the healing part expected in Q2/Q3 2026, and ii) market approval of li

Lhyfe: partnership with Energy Pool

This morning, Lhyfe announced a demand response partnership with Energy Pool, a leading French flexibility operator and distributed energy services provider with more than 8GW of energy production and storage assets under management worldwide. Leveraging the flexibility of Lhyfe's French PEM electr

Mister Spex: first take on Q3 results

This morning Mister Spex posted in-line Q3 revenue marked by a sharp decline in International (-17%) following future store closures, while Germany posted resilient 2% growth. The aEBITDA loss of EUR1.4m was lower than CSSe (-EUR2.7m) thanks to a solid GM expansion of 300bps. FY24 sales and margin